Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 3,158,100 | 3,162,100 | 3,414,400 | 2,936,200 | 2,857,200 |
| Cost of Goods | 404,900 | 457,500 | 540,600 | 317,800 | 297,100 |
| Gross Profit | 2,753,200 | 2,704,600 | 2,873,800 | 2,618,400 | 2,560,100 |
| Operating Expenses | 1,737,600 | 1,758,400 | 1,727,600 | 1,395,500 | 1,450,300 |
| Operating Income | 1,016,500 | 946,700 | 1,146,800 | 1,223,700 | 1,109,900 |
| Interest Expense | 18,900 | 18,000 | 17,400 | 15,300 | 13,100 |
| Other Income | 85,300 | -70,700 | 195,300 | 301,400 | -133,600 |
| Pre-tax Income | 1,082,900 | 858,000 | 1,324,700 | 1,509,800 | 963,200 |
| Income Tax | 114,500 | 40,200 | 127,600 | 194,100 | 111,100 |
| Net Income Continuous | 968,400 | 817,800 | 1,197,100 | 1,315,700 | 852,100 |
| Net Income | $968,400 | $817,800 | $1,197,100 | $1,315,700 | $852,100 |
| EPS Basic Total Ops | 9.05 | 7.64 | 11.18 | 12.31 | 7.90 |
| EPS Basic Continuous Ops | 9.05 | 7.64 | 11.19 | 12.31 | 7.90 |
| EPS Diluted Total Ops | 8.50 | 7.17 | 10.48 | 11.66 | 7.47 |
| EPS Diluted Continuous Ops | 8.50 | 7.17 | 10.48 | 11.66 | 7.47 |
| EPS Diluted Before Non-Recurring Items | 8.79 | 8.44 | 10.96 | N/A | N/A |
| EBITDA(a) | $1,119,600 | $1,046,200 | $1,246,900 | $1,316,300 | $1,184,300 |